TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
EXEL

Exelixis Inc

Healthcare · Biotechnology

58.40$ -0.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Cash Flow

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Cash Flow EXEL
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-19.7% +151.0% +26.8% -60.3% +91.8% -9.5% -8.1% +110.0% +26.3%
-41.2% -28.7% +18.5% +554.5% +7.5% +9.5% +49.1% +53.2% +23.2% +12.0% +0.9%
+119.6% +4.3% +4.5% +85.2% +27.7% +85.6% +14.0% -10.2% -1.1% -11.8% +20.4%
+139.9% +44.5% -56.9% -1,302.0% -3.4% +58.2% -21.1%
-103.1% -159.8%
-5.7% +281.0% +1,141.5% +57.5% -61.5% +136.4% +111.6% +115.6% +17.7% -59.4% -39.7%
-65.8% -531.4% -932.1% +97.2% -77.7% -67.3% +1,122.9% -94.9% +333.3%
-100.7% +669.3% +59.8% +15.4% +30.8% +405.0% -21.8% -2,404.2% +18.5% +45.3%
-62.6% -86.9% +32,211.0% -100.0%
+133.2% -87.0% -958.0% +29.5% -300.2% -41.1% -93,282.9% +15.2% +54.2%
-83.6% +213.2% +305.2% -137.4% +551.9% -147.0%
-29.4% +164.7% +34.4% -65.3% +88.4% -33.4% -24.0% +272.0% +33.2%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?